Skip to Content

Armata Pharmaceuticals Inc ARMP

Morningstar Rating
$3.15 +0.15 (5.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ARMP is trading at a 55% premium.
Price
$3.15
Fair Value
$2.58
Uncertainty
Extreme
1-Star Price
$37.92
5-Star Price
$1.18
Economic Moat
Svfw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARMP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.00
Day Range
$3.003.15
52-Week Range
$1.075.26
Bid/Ask
$3.00 / $3.24
Market Cap
$113.89 Mil
Volume/Avg
5,398 / 12,554

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
75

Comparables

Valuation

Metric
ARMP
ALVR
MORF
Price/Earnings (Normalized)
Price/Book Value
0.764.21
Price/Sales
Price/Cash Flow
Price/Earnings
ARMP
ALVR
MORF

Financial Strength

Metric
ARMP
ALVR
MORF
Quick Ratio
0.3618.3837.20
Current Ratio
0.3818.4838.17
Interest Coverage
−17.80
Quick Ratio
ARMP
ALVR
MORF

Profitability

Metric
ARMP
ALVR
MORF
Return on Assets (Normalized)
−69.35%−52.15%−18.85%
Return on Equity (Normalized)
−65.46%−19.43%
Return on Invested Capital (Normalized)
−72.58%−59.04%−23.26%
Return on Assets
ARMP
ALVR
MORF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
PhnqhdtqhsQsy$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
WpmlrmmkmKrhkcz$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
MhnpcvvnNthpc$121.2 Bil
Moderna Inc
MRNA
RdzwwgxvnZvfh$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
RxdwfdtvcTgkttdg$33.0 Bil
argenx SE ADR
ARGX
PskrznrkmKsrz$27.9 Bil
BioNTech SE ADR
BNTX
XmvyxrndYjq$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
LrrzjgkqQtgtrm$16.1 Bil
United Therapeutics Corp
UTHR
VgdwyfhpjVgtzf$14.3 Bil
Incyte Corp
INCY
WkhdbzvhjJqwvkfj$12.5 Bil

Sponsor Center